Tumor-cell-targeted cytokine gene transfer in experimental models for cancer therapy

The genetic manipulation of tumor cells to express immunostimulatory molecules provides a current approach for the analysis of immune reactions against tumor cells in vivo. Experiments with multiple cytokines have demonstrated that an array of different host effector cells can be recruited by different cytokines in vivo, but more studies are necessary to distinguish cytokine-specific effects from as yet uncharacterized influences of different tumor models. A technically feasible clinical application of this approach is to be seen in the generation of vaccines by introducing such immunostimulatory genes into cancer cells and boosting systemic immune reactions against the unmodified cells. The experimental basis of these vaccination studies is critically discussed.

[Pleural malignant mesothelioma complicated with disseminated intravascular coagulation]

Three cases of MPM complicated with DIC were reported in a total of 6862 autopsies (0.04%) from 1950 to 1989 year in our university hospital. All the three cases showed hemorrhagic patches, shock, decreased platelets and fibrinogen, and prolonged prothrombin and thrombin time. Hyaline thrombosis was observed in the pulmonary interstitial microvessels. We have also discussed the diagnosis and pathogenesis of DIC.

Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis

Tumor necrosis factor (TNF) produced by tumor cells after gene transfer can effectively suppress the growth of locally growing tumors. We wanted to test the effects of "local" TNF on the growth of a highly metastatic cell line. Therefore, a recombinant retrovirus allowing expression of the TNF gene by the beta-actin promotor has been constructed and used to infect the two tumor cell lines EB and ESB, which grow as solid tumor or metastasize, respectively. Expression of TNF by EB cells resulted in their rapid and dose-dependent rejection. In sharp contrast, mice injected with ESB cells producing similar amounts of TNF showed no signs of tumor suppression, but rather had reduced survival rates that correlated with enhanced hepatic metastases. The accelerated formation of liver metastases by ESB TNF cells could be reversed by an anti-TNF mAb. These results demonstrate the opposite effects TNF may have on tumor growth: suppression of a locally growing tumor and promotion of metastasis formation.

Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma

Interleukin (IL)-2, IL-4, IL-7, tumor necrosis factor (TNF), or interferon-gamma (IFN-gamma) has been shown to be able to induce tumor rejection if produced locally by the tumor cells after gene transfer. To analyze whether the cellular rejection mechanisms are different or redundant we have expressed the cytokines in the same tumor cell line (J558L). Cell depletion experiments revealed that all cytokines required CD8+ T cells for complete long-term tumor eradication, although effective but transient host-dependent tumor suppression was also observed in the complete absence of CD8+ T cells. The transient tumor suppression induced by IL-2, IL-4, TNF, or IFN-gamma was also operative in nude and severe combined immunodeficient mice, whereas only tumor suppression induced by IL-7 was dependent on the presence of CD4+ T cells and was not evident in nude mice. The T-cell-independent effector arm of IL-2 and IFN-gamma but not IL-4 and TNF was mediated in part by natural killer cells. The transience of tumor suppression in the absence of T cells reflected loss of cytokine production in the case of TNF, IL-2, and IL-4 but not IFN-gamma. Immunohistologic analysis revealed all cytokine-producing tumors to be heavily infiltrated by macrophages. IL-4 and IL-7 tumors additionally contained eosinophils. The infiltration by T cells did not necessarily reflect their contribution to tumor rejection. Thus, the different cytokines activate heterogeneous transient tumor-suppressive mechanisms but always require CD8+ T cells for complete tumor rejection.

[A clinicopathological and immunohistochemical study of 49 cases of necrotizing lymphadenitis]

A clinicopathological and immunohistiochemical study of 49 cases of necrotizing lymphadenitis was made. Twenty-four patients were male and twenty-five female with the M:F ratio of 0.96:1. The patients ranged in age from 9 to 62 years with a mean of 26. Forty-nine patients had superficial lymphadenopathy, and twenty-two were accompanied by fever. The results also showed that there was multifoci necrosis present in the involved lymph nodes, particularly in the cortex or/and paracortex, with variable numbers of small lymphocytes, immunoblasts, histocytes and phagocytes, the latter with phagocytized nuclear debris derived from necrotizing T lymphocytes. However, granulocytes and plasmacytes were generally absent, and B lymphocytes rare. The pathogenesis of this disease remains unknown and the pathogen has not been found by Gram, Giemsa, PAS, Ziehl-Neelsen and Warthin-Starry stain. The diagnosis, differential diagnosis and etiology of this disease are discussed. We support the suggestion that this entity be called "Kikuchi-Fujimoto's disease" rather than "Histiocytic necrotizing lymphadenitis".

Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant

The potential of tumor cells (J558L) engineered to produce one of 5 different cytokines (interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or gamma-interferon) to give rise to systemic immunity protective against a contralateral challenge with the parental cells was analyzed. The rejection of all cytokine-producing cells appeared to induce some systemic response capable of mediating the rejection of low numbers of subsequently contralaterally injected cells, but the effect was much less obvious with higher cell numbers. The injection of any possible combination of two of the cytokine producers did not reveal any synergistic effects. The cytokine gene-transfected tumor cells were not superior to the parental cells admixed with the adjuvant Corynebacterium parvum with respect to their potential as immunogens to induce immunity.

Differential disruption of simple drawing movements in patients with unilateral brain lesion

In examining the ability of patients with unilateral brain lesion to copy simple drawings of a house and a human face, 18 apoplectic patients confirmed by CT scanning were studied. We found that their drawing of a house was inferior to that of a face in 19 tests (90.5%) of 17 patients (94.4%). Marked differences existed in nearly 90% of these tests. No difference was found between the right-hemisphere and left-hemisphere group, except that more patients of the right-hemisphere group showed contralateral neglect, but in the house drawings only.

Anti-presynaptic membrane receptor antibodies in myasthenia gravis

Myasthenia gravis (MG) is considered as an autoimmune disease of neuromuscular junction resulting from antibodies directed to acetylcholine receptors (AChR). We describe the use of beta-bungarotoxin (beta-BuTx) and alpha-bungarotoxin (alpha-BuTx) to capture their corresponding proteins from preparation of crude human muscle receptor. beta-BuTx binds to presynaptic membrane receptor (PsmR) of the whole receptor fraction, while alpha-BuTx binds to AchR. The captured proteins were used as antigen in ELISA to detect antibodies to PsmR and to AchR in sera from 82 Chinese patients with MG and in controls. In MG, antibodies to PsmR only were detected in 13%, to AchR only in 11% and both to PsmR and AchR in 54%. Only 3 of 50 patients with other neurological diseases and none of 50 healthy subjects had these antibodies. Specificity tests for antibodies showed that the detection systems which we used are specific and confident. No correlation was found between antibody levels and clinical status. The significance of the PsmR antibodies in the pathogenesis of MG is unknown. We suggest that myasthenia gravis is not only due to damage of the postsynaptic membrane, but of presynaptic structures as well.

Effect of radix Salviae miltiorrhizae extract injection on survival of allogeneic heart transplantation

The effect of Radix Salviae Miltiorrhizae (RSM), a commonly used herbal blood circulation invigorator for the treatment of blood stasis in traditional Chinese medicine, on the duration of allograft survival following heterotopic heart transplantation in experimental animals was observed. The results in three heart transplantation models--auricular free graft in mice, abdominal graft in rats and cervical graft in rabbits--suggested that RSM injection in an appropriate dosage prolonged the survival time of cardiac allograft. The herb showed no significant toxicity. It was also found that RSM injection had a synergic effect with corticosteroids against graft rejection.

Heterogeneity of mRNA and protein products arising from the protein 4.1 gene in erythroid and nonerythroid tissues

Immunologically cross-reactive isoforms of the cytoskeletal element protein 4.1 have been identified in many tissues in which they exhibit heterogeneity of molecular weight, abundance, and intracellular localization. To examine the basis for isoform production in erythroid and nonerythroid tissues, we have compared the structure and expression of cDNAs isolated from human erythroid and nonerythroid sources. We have encountered cDNAs representing many distinct mRNA sequences. These exhibit complete nucleotide sequence homology along most of their lengths. Differences were confined to five sequence blocks designated Motifs I-V, which were present or absent in each mRNA moiety. Motif I was expressed only in erythroid cells; it encodes 21 amino acids in a well-characterized spectrin/actin binding domain. Motif II, located near the COOH terminus of the 80-kD "erythroid" protein 4.1 molecule is present in the vast majority of transcripts from both erythroid and nonerythroid cells. Motifs IV and V alter the 5' untranslated region: simultaneous insertion of Motif IV and deletion of Motif V in the untranslated region inserts a new initiator methionine and establishes a contiguous open reading frame encoding a novel 135-kD protein 4.1 molecule. By immunochemical analysis we have identified the longer isoform in cells. Our results are most consistent with tissue-specific alternative mRNA splicing of transcripts of the protein 4.1 gene to yield numerous isoforms. These isoforms exhibit tissue specificity and alter strategic portions of the molecule. Moreover, we describe a novel high molecular weight form of protein 4.1 that arises by splicing events which allow translation at an upstream site.

[Effect of oxymatrine on prolonging the survival time of cardiac tissue allograft in mice and its immunologic mechanisms]

Oxymatrine is an extract from Sophora flavescens Ait. A daily dose of 75 mg/kg or 225 mg/kg of oxymatrine was given to the recipient intramuscularly for 14 days. The survival time of cardiac tissue allograft was prolonged significantly to 12.2 days (at the dose of 75 mg/kg, P less than 0.05) and 15.7 days (at the dose of 225 mg/kg, P less than 0.001) by oxymatrine, while that in the control group was 10.8 days. The effects of oxymatrine on immune-function in BABL/c mice with or without heart allograft were further studied. Experiments showed that in vitro spontaneous proliferation of spleen cells increased markedly on the 10th day after transplantation, while the proliferation response to Con A of spleen cells decreased. The spontaneous proliferation and proliferation responses to Con A or to LPS of spleen cells could be inhibited significantly in normal mice by oxymatrine. The proliferation response to LPS of spleen cells and RPFC was inhibited obviously in transplanted mice by oxymatrine. However, oxymatrine did not affect the proliferation response to Con A of spleen cells, which had been decreased after transplantation. The results suggested that this drug exhibited selective immuno-suppression on function of B cells without obvious effect on T cell function in transplanted mice. This characteristics of the drug seemed beneficial for avoiding side-effect produced by the conventional immuno-suppressive agents.

Structure and evolution of mouse interleukin 6 gene

Restriction fragment length polymorphism in the interleukin 6 gene of murine rodents extending phylogenetically from Mus musculus domesticus to the rat has been analyzed. Most species exhibit distinct restriction site patterns. In contrast, limited polymorphism was found in the tumor necrosis factor alpha gene indicating different selective pressure acting on both genes. The gene encoding interleukin 6 was isolated from a genomic library and the exon/intron organization was determined by restriction analysis and limited DNA sequence analysis. It consists of five exons which distribute over about seven kilobases, thus resembling in structure and organization the human counterpart. Furthermore, no restriction fragment length polymorphisms in the interleukin 6 gene of autoimmune strains NZB, NZW, MRL-lpr/lpr and BxSB could be detected for either EcoRI, BamHI or HindIII.

Altered glycosylation of membrane glycoproteins in human uroepithelial cell lines

Total cellular glycopeptides of 7 human uroepithelial cell lines that differ in the grade of transformation (TGr) were analysed by gel filtration and affinity chromatography on immobilized lectins. The 4 cell lines that are tumorigenic in nude mice and invasive in vitro (TGr III) possess more highly branched, tri- and tetraantennary N-acetyllactosaminic glycans, with less biantennary glycans than the 2 non-tumorigenic, noninvasive (TGr II) cell lines examined. The only exception to this general pattern is the third cell line, which is classified as TGr II. The cellular glycopeptide distribution pattern in this cell line is similar to that of the TGr III cells. The possible relationship between altered glycosylation of membrane glycoproteins and the expression of a malignant phenotype is discussed.

Development of an anticomplement immunoenzyme test for detection of EB virus nuclear antigen (EBNA) and antibody to EBNA

An anticomplement immunoenzyme test was developed by conjugating anti-human C3 antibody with horseradish peroxidase. EBNA could be detected by this test in all cell lines related to EB virus, as well as in nasopharyngeal carcinoma cells, but not in unrelated cell lines. Antibody to EBNA could also be detected. The test is sensitive and does not require a fluorescence microscope which makes it particularly suitable for mass survey.